Author: admin

香港 – EQS Newswire – 2026年3月27日 – 综合性生物制药公司 — 联康生物科技集团有限公司（「联康集团」或「本公司」，连同其附属公司统称「本集团」，股份代号：0690）欣然宣布本集团截至二零二五年十二月三十一止年度(「年内」）的全年业绩。

二零二五年取得之重大成就
年内，本集团取得了一系列成就，在已上市产品及创新的生物制剂方面均取得良好成绩。主要取得的成就如下:

1. 年内，本集团录得破纪录的财务业绩，收入按年增长6. 0%，达到约586. 2百万港元。溢利按年升12.7%至约93.3百万港元，而纯利率按年增加1. 0个百分点至15.9%，创历史新高。每股盈利达到约1. 56港仙，按年增长15.5%，二零二三年至二零二五年的复合年增长率为18.55%。
2. 本集团于年内录得稳健的经营现金流，经营现金流量及自由现金流量分别按年增加32.7%及27.3%。现金比率由二零二四年底的0.53倍上升至二零二五年底的1.63倍。现金转换周期从124天改善为107天，突显营运效率显著提升。凭借可持续盈利及稳健的现金流，董事会建议派发末期股息每股0.313港仙。
3. 自博固泰®于二零二四年三月正式推出以来，在稳健的商业化策略及成功的学术推广驱动下，其保持了强劲的增长势头。于二零二五年，博固泰^®在中国展现出快速的市场渗透率，年收入增长实现111.0%的显著增长。
4. 于二零二五年五月，本集团第二款眼部产品金因康^®（地夸磷索钠滴眼液）获中国国家药品监督管理局(NMPA)的上市批准，标志着继金因舒^®后，本集团眼部产品线拓展之重要里程碑。本集团正积极筹备其推出及营销策略。除利用与金因舒^®及其成熟的在线及线下分销网络的协同效应以实现快速市场渗透外，金因康^®将专门针对医院场景以外的中高端干眼症患者群体，即该等优先考虑长期疗效及优质产品质量的患者。
5. 于二零二五年六月，本集团正式推出肌颜态^®高端系列GeneQueens^®及医疗器械品牌金因敷^®，此举标志其进军「药品、医械及医美」整合领域之两个关键里程碑。该等产品发布反映本集团致力于完善其皮肤健康产品矩阵，并满足消费者对功能性护肤及医美术后修复领域中以功效为导向的医学级护肤品不断演变的需求。
6. 于二零二五年七月，硫酸艾沙康唑胶囊的上市申请已获国家药品监督管理局正式受理。硫酸艾沙康唑胶囊预计最早将于二零二六年第四季度获准上市，为侵入性真菌感染患者提供更安全、更有效且高质量的治疗选择。
7. 于二零二五年，本集团与温州医科大学建立战略合作伙伴关系，利用该大学在bFGF生产方面经证实的专业知识，共同研发结合EGF及bFGF的热敏凝胶制剂。作为再生医学的关键生长因子，bFGF在促进肉芽组织增生及血管生成方面具有高度疗效。
8. 于二零二五年底，本集团将其长期战略由「稳健增长」重新定位为「创新驱动」，标志着其由一家综合制药公司大胆转型为全球再生医学先驱。本集团正推进具变革性的研发战略方向，涵盖四大关键领域：肌肉骨骼再生、皮肤再生、眼部再生及耳鼻喉科再生。

全年业绩

于二零二五年，本集团录得收益约586. 2百万港元，按年增长6. 0%。博固泰^®的收益由约63.5百万港元大幅增加至约134.0百万港元，大幅增加111.0%。金因肽^®的收益约为220.4百万港元，按年增长10.9%。由于市场竞争激烈，金因舒^®的收益由约41.9百万港元按年减少7.9%至约38.6百万港元。匹纳普^®录得的收益由约244.2百万港元减少29.4%至约172.5百万港元。二零二五年，本集团在带量采购下采取了更为严谨且具选择性的医院供应策略，以保障利润率，特别是在政策调整加剧价格竞争的地区。同时，本集团加速向传统医院渠道以外的药房网络多元化发展，并优化其供应链以改善成本及盈利能力。于二零二四年，博舒泰^®成功纳入河南省十七省联盟集中带量采购，采购有效期设定为两年。于二零二五年，许多省份的医院开始采购博舒泰^®。继二零二四年的去库存及较低基数之后，来自博舒泰^®的收益由约10.2百万港元增加至约15.5百万港元，大幅增加51.9%。肌颜态^®在其早期阶段产生约2.8百万港元的收益。有限的收益规模反映了几项因素，包括于年内获批准及推出的产品数量相对较少，以及专业营销及分销团队仍处于组建及优化阶段的事实。

毛利约为487.6百万港元，较二零二四年的约461.1百万港元增加5.7%，而毛利率按年下降0.2个百分点至83.2%。本集团实现约93.3百万港元的破纪录溢利，再次创下新高，按年增长12.7%。净利润率按年上升1.0个百分点至15.9%。该等业绩证明本集团凭借强大的商业化执行力及财务纪律，成功将产品创新转化为市场价值。每股盈利约达1.56港仙，按年增长15.5%。

展望

再生医学已成为一个快速发展的领域，专注于利用细胞、组织或遗传物质修复、更换或再生受损的组织或器官。该行业具有治疗及解决慢性病及晚期疾病潜在病因的潜力。全球再生医学市场于二零二五年约为517亿美元。预计将由二零二六年的630亿美元增长至二零三四年的5,556亿美元，复合年增长率为31.3%。慢性病及遗传性疾病日益普遍，加上发达及新兴市场的医疗保健支出不断增加，预计将支持再生医学行业持续增长。

联康生物科技集团主席梁国龙先生表示：「二零二五年，我们欣然宣布公司又实现了一年的营利突破，标志着集团发展中重要的里程碑。年内，本集团进入策略发展的新阶段。随着市场环境逐步向好，我们积极推进由『稳定增长』转型至『创新驱动』阶段，聚焦肌肉骨骼再生、皮肤再生、眼部再生及耳鼻喉再生四大多元化治疗领域。

随着多项产品正在研发并加速迈向商业化阶段，集团持续拓展多元化营销渠道。在巩固传统医疗网络、加深与本地经销商合作以及开展学术推广活动的同时，我们亦积极布局在线电商平台，以进一步提升产品可及性以及扩大市场覆盖。我们的发展战略不限于中国市场。年内，我们与科兴制药建立了战略合作关系，共同推动博固泰^®的全球化布局。通过此次合作，我们已授权博固泰^®在沙特阿拉伯、埃及、摩洛哥、哥伦比亚、阿根廷及墨西哥六个国际市场的独家商业化权利，为全球业务拓展奠定坚实基础。我们预计上述市场最早将于2026年底开始贡献收益。与此同时，我们正积极推进博固泰^®在美国的FDA注册审批。

二零二五年十二月，我们与温州医科大学及温州市瓯海区人民政府达成战略合作，致力于构建『政产学研』的协同模式，进一步提升公司在再生医学领域的能力。凭借地方政府与顶尖学术机构的有力支持，我们有信心打造一流的生物医药生态体系，以提升全周期能力。」
Hashtag: #Uni-BioScience #联康生物科技

The issuer is solely responsible for the content of this announcement.

关于联康生物科技集团有限公司

联康生物科技集团有限公司是一家于2001年在香港联合交易所主板上市的创新型生物医药企业（股票代码：00690.HK），致力于以下一代合成生物学技术与复杂多肽创新，驱动再生医疗发展。本集团聚焦于骨骼/肌肉再生、皮肤再生、眼部再生及耳鼻喉（ENT）再生四大核心研究领域，构建了涵盖生物创新药、高值仿制药与医疗美容等板块的多元化产品管线。本集团分别于北京、东莞及深圳均设有GMP的生产基地，具备研发、生产及商业化销售的全链条能力。本集团致力于成为再生医学领域的全球领导者，重新定义科学如何修复与延展人类生命。

如欲了解更多信息，请联系： ir@uni-bioscience.com

HONG KONG SAR – EQS Newswire – 27 March 2026 – A fully integrated biopharmaceutical company – Uni-Bio Science Group Limited (“Uni-Bio Science”, together with its subsidiaries referred to as the “Group”, stock code: 0690.HK), is pleased to announce its annual results for the year ended 31 December 2025 (the “Year”).

Key Accomplishments in 2025
During the Year, the Group achieved a spectrum of accomplishments, for both of its marketed products and innovative biologics. The key highlights include:

1. During the Year, the Group delivered record-breaking financial results, with revenue recorded a 6.0% year-on-year (“YoY”) increase, reaching approximately HK$586.2 million. Profit for the year soared by 12.7% YoY to approximately HK$93.3 million, and net profit margin increased by 1.0 percentage points YoY to 15.9%, marking a historic high. The earnings per share reached approximately HK$1.56 cents, reflecting a growth of 15.5% YoY or a CAGR of 18.55% from 2023 to 2025.
2. The Group generated solid cash from operations in the Year, operating cash flow and free cash flow increased by 32.7% and 27.3% YoY, respectively. Cash ratio increased from 0.53 times at the end of 2024 to 1.63 times at the end of 2025. The cash conversion cycle improved from 124 days to 107 days, highlighting greater operating efficiency. Backed by sustainable earnings and a healthy cash flow, the board of directors (“Board”) has declared a dividend payment for 2025 of HK$0.313 cents per share.
3. Since its official launch in March 2024, Bogutai^® has sustained strong growth momentum, driven by a solid commercialization strategy and successful academic engagement. In 2025, Bogutai^® demonstrated rapid market adoption in China, achieving a remarkable year-on-year revenue growth of 111.0%.
4. In May 2025, the Group’s second ophthalmology product, 金因康^® (Diquafosol Sodium Eye Drops), received marketing approval from the China National Medical Products Administration (“NMPA”), marking a significant milestone in expanding the Group’s ophthalmic portfolio following GeneSoft^®. The Group is actively preparing its launch and marketing strategy. In addition to leveraging synergy with GeneSoft^® and its established online and offline distribution network for rapid market penetration, 金因康^® will specifically target the mid-to-high-end segment of dry eye patients outside the hospital setting, those who prioritize long-term efficacy and premium product quality.
5. In June 2025, the Group officially launched the high-end series GeneQueens^® of 肌顏態^® and the medical device brand 金因敷^®, marking two key milestones in its strategic expansion into the integrated”Drug, Medical Device, and Aesthetics”field. These product launches reflect the Group’s commitment to enhancing its skin health product matrix and addressing evolving consumer needs for efficacy-driven, medical-grade skincare in both functional skincare and post-aesthetic recovery.
6. In July 2025, the marketing application of Isavuconazonium sulfate capsules were officially accepted by the NMPA. Isavuconazonium sulfate capsules are expected to be approved for launch as early as the fourth quarter of 2026, offering a safer, more effective, and high-quality treatment option for patients suffering from invasive fungal infections.
7. In 2025, the Group established a strategic partnership with Wenzhou Medical University to explore a thermosensitive gel formulation combining EGF and bFGF, leveraging the university’s proven expertise in bFGF production. As a key growth factor in regenerative medicine, bFGF is highly effective in promoting granulation and angiogenesis.
8. Towards the end of 2025, the Group repositioned its long-term strategy from “Stable Growth” to “Innovation-Driven,” signifying a bold transformation from an integrated pharmaceutical company into a global pioneer in regenerative medicine. The Group is advancing a transformative R&D strategy spanning four key areas: muscular-skeletal regeneration, skin regeneration, ocular regeneration, and ENT regeneration.

Annual Results
For 2025, the Group recorded a revenue of approximately HK$586.2 million, representing an increase of 6.0% YoY. Revenue from Bogutai^® increased from approximately HK$ $63.5 million to approximately HK$ 134.0 million, representing a significant increase of 111.0%. Revenue generated from GeneTime^® was approximately HK$220.4 million, representing an increase of 10.9% YoY. GeneSoft^® recorded a 7.9% YoY decrease in revenue from approximately HK$41.9 million to approximately HK$38.6 million due to intense market competition. Pinup^® recorded a decrease of 29.4% in revenue from approximately HK$244.2 million to approximately HK$172.5 million for the Year. In 2025, the Group adopted a more disciplined and selective hospital-supply strategy under volume-based procurement (VBP) to safeguard margins, particularly in regions where policy adjustments intensified price competition. At the same time, the Group accelerated diversification into pharmacy networks beyond traditional hospital channels and optimized its supply chain to improve cost and profitability. In 2024, Boshutai^® was successfully included in the VBP by the Henan Seventeen Provinces Alliance and the procurement validity period is set for two years. Hospitals in many provinces began procuring Boshutai^® in 2025. Following the destocking and a low base in 2024, revenue from Boshutai^® increased from approximately HK$10.2 million to approximately HK$15.5 million, representing a significant increase of 51.9%. 肌顏態^® generated approximately HK$2.8 million in revenue in its early stage. The limited revenue scale reflected several factors, including a relatively small number of products approved and launched during the Year, and the fact that specialized marketing and distribution teams were still being built and optimized.

Gross profit was approximately HK$487.6 million, representing an increase of 5.7% as compared with approximately HK$461.1 million in 2024, and gross profit margin increased by 0.2 percentage points YoY to 83.2%. The Group delivered another year of record-breaking profit, achieving approximately HK$93.3 million for the Year, representing an increase of 12.7% YoY. Net profit margin increased by 1.0 percentage points YoY to 15.9%. These results demonstrate the Group’s success in converting product innovation into market value through strong commercialization execution and financial discipline. The earnings per share reached approximately HK$1.56 cents, reflecting a growth of 15.5% YoY.

Prospects
Regenerative medicine has emerged as a rapidly developing field, focused on repairing, replacing, or regenerating damaged tissues or organs using cells, tissues, or genetic material. The sector has the potential to treat and address the underlying causes of chronic and advanced diseases. The global regenerative medicine market was approximately USD51.7 billion in 2025. It is projected to grow from USD63.0 billion in 2026 to USD555.6 billion by 2034, representing a compound annual growth rate (CAGR) of 31.3%. The increasing prevalence of chronic and hereditary diseases, together with rising healthcare expenditure in both developed and emerging markets, is expected to support continued growth in the regenerative medicine industry.

Mr. Kingsley Leung, Chairman of Uni-Bio Science, commented, “In 2025, we are proud to have delivered another year of record profitability, marking a significant milestone in our growth journey. During the year, we entered a new phase of strategic development. In anticipation of an increasingly favorable market environment, we advanced our strategic transition from ‘stable growth’ to ‘innovation-driven’ development, with a clear focus on four diversified therapeutic areas: musculoskeletal regeneration, skin regeneration, ocular regeneration, and ENT regeneration.

With multiple products progressing through our pipeline and accelerating toward commercialization, the Group has continued to broaden its marketing channels. In addition to strengthening our established offline hospital networks, deepening partnerships with local distributors, and hosting academic conferences, we have actively expanded into online e-commerce platforms to enhance product accessibility and extend our market reach. Our ambitions extend well beyond China. During the year, we formed a strategic partnership with Kexing Biopharm to accelerate the global expansion of Bogutai^®. Through this collaboration, we have granted Kexing Biopharm exclusive commercialization rights for Bogutai^® in six international markets—Saudi Arabia, Egypt, Morocco, Colombia, Argentina, and Mexico—laying a solid foundation for global growth. We expect these markets to begin contributing revenue as early as the end of 2026. At the same time, we are advancing the FDA approval process for Bogutai^® in the United States, aiming for approval as early as 2027.

In December, we also entered into a strategic collaboration with Wenzhou Medical University and the People’s Government of Ouhai District, Wenzhou, to foster a synergistic ‘government–university–enterprise’ model, further strengthening our capabilities in regenerative medicine. Supported by strong partnerships with local governments and leading academic institutions, we are well positioned to build a world-class biomedical ecosystem and enhance our end-to-end innovation capabilities.”
Hashtag: #Uni-BioScience

The issuer is solely responsible for the content of this announcement.

About Uni-Bio Science Group Limited

Uni-Bio Science Group Limited is an innovative biopharmaceutical enterprise listed on the Main Board of The Stock Exchange of Hong Kong Limited in 2001 (Stock Code: 00690.HK). The Group is committed to powering the advancement of regenerative medicine with next-generation synthetic biology and complex peptide innovation. Focusing on four core research areas—muscular-skeletal regeneration, skin regeneration, ocular regeneration, and ENT regeneration—the Group has built a diversified product pipeline encompassing innovative biologics, high-value generic drugs, and medical aesthetics. The Group operates GMP-compliant production bases in Beijing, Dongguan, and Shenzhen, with fully integrated capabilities spanning R&D, manufacturing, and commercial sales. Uni-Bio Science Group is dedicated to be the global leader in regenerative medicine, redefining how science restores and extends human life.

For further information, please contact: ir@uni-bioscience.com

BINZHOU, CHINA – Media OutReach Newswire – 27 March 2026 – Recently, the second National Showcase of Outstanding Works from China’s Rare Operatic Genres , titled “Ancient Echoes, Treasured Legacies,” was held in Boxing County, Binzhou City, Shandong Province. The event was co-organized by the China Theatre Association, the Shandong Federation of Literary and Art Circles, and other cultural organizations.

Rare operatic genres, often referred to as endangered theatrical forms, are typically characterized by strong regional identities, limited reach, scarce inheritors, and relatively small scale. Shaped over centuries, they embody distinctive musical styles and performance forms of high artistic value and deep cultural resonance. As an integral part of intangible cultural heritage, they preserve local dialects, customs, and cultural ideals..Their protection, transmission, and revitalization are essential to strengthening the foundations of Chinese opera and advancing the creative transformation and innovative development of traditional Chinese culture.

This year’s showcase drew participation from over 100 troupes nationwide, with 36 outstanding works selected. Covering genres such as Yong Opera, Qian Opera, Qi Opera, Dunqiang, and Yong Opera, the showcase highlighted recent progress in safeguarding and revitalizing China’s rare operatic traditions.

Hashtag: #BinzhouInformationOffice

The issuer is solely responsible for the content of this announcement.

SINGAPORE – Media OutReach Newswire – 27 March 2026 – The Institute of Singapore Chartered Accountants (ISCA), together with its Professional Services (PS) Centre Alliance partners, comprising Association of Small & Medium Enterprises, Institute of Valuers & Appraisers, Singapore Business Federation (SBF), Singapore Chinese Chamber of Commerce & Industry (SCCCI), Singapore Manufacturing Federation, Tax Academy of Singapore and the Law Society of Singapore, has launched the PS Centre in Nanjing. This marks the Alliance’s second PS Centre in China and its third globally, strengthening a growing network to support enterprises expanding across China, Singapore and Southeast Asia.

Amid rising demand from businesses seeking overseas growth, the PS Centre was established as a trusted platform to connect enterprises with trusted professional services expertise and in-market networks, enabling smoother and more effective cross-border expansion. Nanjing is strategically positioned, with strong linkages to universities that support talent pipelines, as well as ecosystem builders such as the Singapore-Nanjing Eco Hi-tech Island that help businesses establish and maintain operational presence in the market.

Since its inception, the PS Centres in China and Vietnam have provided on-the-ground support and facilitated opportunities for over 100 businesses. Prior to the launch in Nanjing, the PS Centre has already supported several Small and Medium-sized Enterprises (SMEs) in establishing operations and building local teams. One such example is BIPO, a HR solutions provider, which successfully set up its presence in Nanjing with support from the PS Centre ecosystem.

Mr Michael Chen, CEO of BIPO (Asia) shared: “The launch of the Professional Services Centre marks an important step in enabling more efficient and scalable global expansion for enterprises. As companies expand across markets, what they increasingly need is not just individual services, but an integrated ecosystem of professional capabilities. At BIPO, we are proud to partner with ISCA and the broader professional community to provide the HR technology and operational infrastructure that supports this ecosystem, helping businesses build sustainable, compliant, and tech-enabled global operations.”

The launch took place at the forum titled “Bridging Singapore and Nanjing, Charting Opportunities from ASEAN to China“, organised by the PS Alliance and co-hosted by China-Singapore Nanjing Eco-Tech Island Investment Development Co., Ltd. The forum brought together government representatives, professional bodies, financial institutions and business leaders from both Singapore and China.

Mr Xu Feng, Vice Mayor of Nanjing, highlighted the growing economic linkages between China and Southeast Asia: “Nanjing and Singapore share a long-standing friendship built upon a strong foundation of cooperation. We recognise that the international expansion of enterprises relies on the support of professional services. As a global hub for professional services, Singapore offers complementary strengths, and the prospects for collaboration between our two sides are vast. Nanjing will continue to foster a world-class international business environment, enhance its end-to-end support systems for enterprises expanding overseas, and promote mutually beneficial partnerships between enterprises and Singapore’s professional institutions.”

Mr Ernie Koh, Council Member, SBF / Vice-Chairman, Research & Publications Committee, SCCCI said: “Singapore and China share strong and enduring economic ties, and platforms like the Nanjing PS Centre play a critical role in deepening these linkages. By bringing together business networks and professional expertise, the Alliance can better support enterprises in navigating new markets, strengthening their capabilities, and unlocking opportunities across Southeast Asia. This collaboration reflects our shared commitment to enabling sustainable, cross-border growth.”

Mr Daniel Koh, Vice-President, The Law Society of Singapore, said: “As businesses expand across borders, navigating legal and regulatory complexities becomes increasingly critical. The establishment of the PS Centre provides a valuable platform for enterprises to access trusted legal expertise alongside other professional services. By strengthening cross-border collaboration, we can help businesses operate with greater confidence, manage risks effectively, and build resilient foundations for international growth.”

Mr Darren Ku, Council Member, ASME, said: “For many SMEs, internationalisation presents both significant opportunities and challenges. The Nanjing PS Centre offers a practical and structured gateway for businesses to access the professional support they need, from compliance to market entry strategies. By lowering barriers and providing coordinated expertise, the Alliance will empower more SMEs to expand into Southeast Asia with greater confidence and clarity.”

Beyond facilitating business expansion, the Nanjing PS Centre will also anchor talent development and cross-border capabilities. ISCA has established partnerships with key institutions including Nanjing University of Finance and Economics, Nanjing Audit University, and Jiangsu Certified Public Accountants, laying the foundation for a sustainable pipeline of internationally-ready accounting professionals.

ISCA President Mr Teo Ser Luck said: “The Professional Services Centre in Nanjing shows our commitment to helping Chinese and Singapore businesses grow with good governance, proper compliance, and sound financial management as they expand across the region. Through working together, we can help businesses grow with confidence and in a sustainable way. We plan to bring this model to other parts of the world, so we can continue sharing knowledge and networks with businesses operating across borders.”

With regions such as Shenzhen, Johor Bahru, and Bangkok earmarked for new PS Centres, the PS Alliance has highlighted their commitment to supporting businesses in their cross-border endeavours and operations. By providing a platform for them to explore new opportunities for growth and talent development, these PS Centres play a vital role in cross-border professional development.

The launch of Nanjing PS Centre will serve as a platform to integrate professional resources from Singapore and Jiangsu, supporting enterprises investing in Singapore and across ASEAN. This initiative, coupled with future expansion into other regions, further underscores ISCA’s continued role in strengthening cross-border collaboration and enabling resilient, future-ready business growth.

Hashtag: #ISCA #DifferenceMakers #Accounting #Accountancy #CharteredAccountants #ChooseAccountancy #Singapore #China #Nanjing #PSCentre #Alliance

The issuer is solely responsible for the content of this announcement.

Institute of Singapore Chartered Accountants (ISCA)

The Institute of Singapore Chartered Accountants (ISCA) is the national accountancy body of Singapore. Established in 1963, ISCA administers the Singapore Chartered Accountant Qualification programme and is the designated entity by the Singapore Ministry of Finance to confer the Chartered Accountant of Singapore [CA (Singapore)] designation.

ISCA supports over 43,000 members across industries in Singapore and globally, with members in more than 40 countries. With a growing international presence, ISCA has 12 overseas chapters, 7 offices across 10 countries and a network of over 150 strategic partners, strengthening professional connections and opportunities across borders. ISCA is also a member of Chartered Accountants Worldwide, a global network representing more than 1.8 million Chartered Accountants and students across over 190 countries.

ISCA advances professional development and lifelong learning through ISCA Academy, its training arm and drives community impact through ISCA Cares, its charity arm.

For more information, visit www.isca.org.sg.

MANILA, PHILIPPINES – Media OutReach Newswire – 27 March 2026 – Jollibee, the flagship brand of the Jollibee Group, has been ranked the fifth-strongest restaurant brand worldwide in the Brand Finance Restaurants 25 2026 report, reinforcing the brand’s growing global competitiveness and resonance across markets.

The 2026 ranking marks a significant rise from ninth place in 2025, reflecting a measurable strengthening of Jollibee’s global brand equity. Its Brand Strength Index (BSI) improved to 87.9/100 from 83.9 the previous year—one of the most notable gains among ranked restaurant brands—indicating increased consumer familiarity, preference, and advocacy across both established and emerging markets.

In the same report, Brand Finance also noted that Jollibee remains the Philippines’ sole representative among the world’s 25 most valuable restaurant brands, and the only Philippine and Southeast Asian brand included in the global ranking.

Ernesto Tanmantiong, Global President and Chief Executive Officer of the Jollibee Group, said the recognition underscores the brand’s rising global competitiveness and equity.

“Being ranked among the world’s strongest restaurant brands by Brand Finance signals that Jollibee is winning in superior taste and strengthening consumer preference across markets. It reflects the trust we have built, the disciplined execution of our teams, and the growing power of our brand as we continue to deliver joyful experiences to customers worldwide,” Tanmantiong said.

Strengthened global equity

Brand Finance reported that Jollibee’s brand value rose by 32% to USD 3.3 billion in 2026, placing it 18th among the world’s 25 most valuable restaurant brands. As part of its brand strength assessment, Brand Finance cited Jollibee’s AAA brand strength rating, reflecting strong customer trust, emotional connection, and price acceptance in its home market and other key markets, including Singapore and Vietnam.

The year-on-year improvement in brand strength signals that Jollibee is not only expanding its footprint but also deepening its ability to influence customer choice—an important driver of long-term earnings quality, pricing resilience, and franchise attractiveness. This progression positions the brand alongside more established global players in terms of consumer affinity, despite differences in scale.

Brand Finance noted that as the only Philippine and Southeast Asian brand in the global ranking, Jollibee’s performance underscores the ability of home-grown brands to compete internationally through disciplined execution while sustaining strong brand equity and expectations for future earnings. Its continued expansion across Asia, North America, and the Middle East has strengthened long-term growth visibility while preserving brand leadership in its core market.

“We remain focused on building scalable operating systems, reinforcing brand fundamentals, and delivering consistent, superior taste across markets. With disciplined expansion, we are positioning our brands to grow sustainably, compete globally, and create long-term value for our stakeholders, including investors and franchise partners,” Tanmantiong added.

Jollibee’s growing global recognition is reinforced by recent accolades across key international markets. In the United States, the brand was named among the best fast-food fried chicken chains by USA Today, while Eater spotlighted it as a must-visit destination for its iconic Chickenjoy and distinctly Filipino flavors. The brand has also earned recognition in Hong Kong and Singapore, and in Kuwait, where Jollibee was ranked among the top 10 brands for best customer service—underscoring its growing consumer preference and consistent delivery of superior taste and joyful service across markets.

Hashtag: #JollibeeGroup

The issuer is solely responsible for the content of this announcement.

About Jollibee Group

Jollibee Foods Corporation (PSE: JFC) (the “Company”) is one of the world’s fastest-growing restaurant companies, driven by its purpose of spreading joy through superior taste. It manages and operates a portfolio which includes 19 brands (the “Jollibee Group”) with over 10,000 stores and cafés across 33 countries.

The Jollibee Group’s portfolio includes nine (9) wholly-owned brands (Jollibee, Chowking, Greenwich, Red Ribbon, Mang Inasal, Yonghe King, Hong Zhuang Yuan, Smashburger and Tim Ho Wan), five (5) franchised brands (Burger King, Panda Express, Yoshinoya, Common Man Coffee Roasters, and Tiong Bahru Bakery in the Philippines), and ownership stakes in other key brands like The Coffee Bean and Tea Leaf (80%), Compose Coffee (70%), SuperFoods Group that operates Highlands Coffee (60%), and bubble tea brand Milksha (51%). The Company also has membership interests in Tortazo, LLC, along with Chef Rick Bayless, for Tortazo in the U.S. and in Botrista, a leader in beverage technology.

The Jollibee Group’s global sustainability agenda, Joy for Tomorrow, underscores its commitment to sustainable business practices across food safety, employee welfare, community support, good governance, and environmental responsibility, among others. These focus areas are aligned with the United Nations Sustainable Development Goals (UN SDGs).

The Company has been recognized as the Philippines’ Most Admired Company by the Asian Wall Street Journal, named one of Asia’s Fab 50 Companies, and listed among Forbes’ World’s Best Employers and Top Female-Friendly Companies. The Company is also a four-time Gallup Exceptional Workplace Award recipient and featured in TIME’s World’s Best Companies and Fortune’s Southeast Asia 500 List.

MANILA, PHILIPPINES – Media OutReach Newswire – 27 March 2026 – The Jollibee Group has earned the Gallup Exceptional Workplace Awards (GEWA) with Distinction—the highest honor given by Gallup to organizations that demonstrate outstanding commitment to employee engagement and workplace culture.

In the same recognition cycle, the Jollibee Group also received the Gallup Engagement Award for the fifth consecutive year, highlighting the consistency of its people-first approach and reinforcing its standing among organizations that prioritize building highly engaged workplaces.

Notably, the Jollibee Group remains the only Philippine-based company to have received the Gallup Exceptional Workplace Award, underscoring how a Filipino brand can stand shoulder-to-shoulder with global organizations in creating a high-engagement workplace culture.

Highest Top Employer Honors

“Being recognized by Gallup at this level affirms the kind of workplace we are building at the Jollibee Group—one where our people can grow, thrive, and do their best work every day. It also shows that a Filipino company can stand alongside the world’s best workplaces,” said Ernesto Tanmantiong, Global President and CEO, Jollibee Group.

“As we continue to expand globally, we remain committed to building a culture that enables our teams and partners to find joy in their work, succeed together, and bring the joy of our brands to more communities around the world,” he added.

The GEWA with Distinction recognition is awarded to a select group of organizations chosen by Gallup’s review panel for the impact of their strategic initiatives that strengthen employee engagement and help team members perform at their best.

Bringing Choose Joy! EVP to Life

The recognition marks a milestone for the Jollibee Group and reflects the company’s commitment to bringing its Choose Joy! Employer Value Proposition (EVP) to life—creating an environment where employees find purpose in their work, grow their capabilities, and experience genuine care and belonging.

“At the Jollibee Group, engagement is something we build intentionally every day through strong leadership, continuous listening, and meaningful people programs,” said Arsenio Sabado, Global Chief Human Resources Officer of the Jollibee Group.

“At the heart of Choose Joy is our commitment to create an environment where our team members feel a strong sense of purpose, have opportunities to grow their careers, and experience real belonging as part of our organization.”

By embedding employee engagement into its operating model, the Jollibee Group demonstrates that choosing joy at work can drive stronger performance and deeper commitment across teams. The Group views engagement not only as a people initiative but also as a strategic advantage that strengthens execution and supports sustainable long-term growth.

For employees, this approach translates into a workplace where they can build meaningful careers and thrive both professionally and personally. Guided by our Choose Joy! EVP, team members are supported by leadership that values listening, development opportunities that build capability, and a culture that recognizes and cares for its people.

The Gallup recognition adds to a growing list of global and regional honors that affirm the Jollibee Group’s commitment to being a world-class employer. The Group has been included in Forbes’ World’s Best Employers list, recognized among TIME’s World’s Best Companies, and named Employer of the Year by the People Management Association of the Philippines (PMAP)—recognitions that highlight its continued efforts to build a workplace where people can thrive and grow.

As it continues to expand its global footprint, the Jollibee Group remains committed to strengthening its people-first culture, ensuring that engagement, leadership, and meaningful work remain central to its growth and delivery on its purpose of spreading joy through superior taste.

Hashtag: #JollibeeGroup

The issuer is solely responsible for the content of this announcement.

About Jollibee Group

Jollibee Foods Corporation (PSE: JFC) (the “Company”) is one of the world’s fastest-growing restaurant companies, driven by its purpose of spreading joy through superior taste. It manages and operates a portfolio that includes 19 brands (the “Jollibee Group”) with over 10,000 stores and cafés across 33 countries.

The Jollibee Group’s portfolio includes nine (9) wholly-owned brands (Jollibee, Chowking, Greenwich, Red Ribbon, Mang Inasal, Yonghe King, Hong Zhuang Yuan, Smashburger and Tim Ho Wan), five (5) franchised brands (Burger King, Panda Express, Yoshinoya, Common Man Coffee Roasters, and Tiong Bahru Bakery in the Philippines), and ownership stakes in other key brands like The Coffee Bean and Tea Leaf (80%), Compose Coffee (70%), SuperFoods Group that operates Highlands Coffee (60%), and bubble tea brand Milksha (51%). The Company also has membership interests in Tortazo, LLC, along with Chef Rick Bayless, for Tortazo in the U.S. and in Botrista, a leader in beverage technology.

The Jollibee Group’s global sustainability agenda, Joy for Tomorrow, underscores its commitment to sustainable business practices across food safety, employee welfare, community support, good governance, and environmental responsibility, among others. These focus areas are aligned with the United Nations Sustainable Development Goals (UN SDGs).

The Company has been recognized as the Philippines’ Most Admired Company by the Asian Wall Street Journal, named one of Asia’s Fab 50 Companies, and listed among Forbes’ World’s Best Employers and Top Female-Friendly Companies. The Company is also a four-time Gallup Exceptional Workplace Award recipient and featured in TIME’s World’s Best Companies and Fortune’s Southeast Asia 500 List.

香港 – Media OutReach Newswire – 2026年3月27日 – 專業會計服務機構 朗峰會計（SetupHK）今日宣布，即時推出「一小時免費公司稅務診斷」服務，專為香港中小企業而設，名額限定首20位。服務涵蓋帳目狀況評估、報稅安排釐清及稅務風險分析，現正接受 WhatsApp 預約。

此項服務於報稅季節正式推出，配合稅務局每年四月起向各企業陸續發出利得稅報稅表的時間節點。朗峰會計表示，推出是次服務，旨在讓香港中小企老闆在正式委託報稅服務前，先掌握自身帳目的實際狀況，避免因準備不足而錯過申報限期或面對不必要的稅務風險。

服務詳情

是次免費帳目診斷為一對一形式進行，由朗峰會計專業顧問主理，每節約一小時，內容涵蓋三個範疇：

帳目狀況評估 — 審視企業現有帳目的完整性及準確度，識別潛在問題。

報稅安排釐清 — 根據公司架構及財政年度，釐清當前需要完成的申報步驟及時間表。

稅務風險分析 — 初步識別企業面對的稅務風險，包括逾期申報、帳目不符及常見錯漏等。

名額限定首20位，先到先得，額滿即止。預約方式：WhatsApp 852-9248-5734。

背景

根據香港稅務條例，香港有限公司須每年提交利得稅報稅表（BIR51），並同時附上經執業核數師審核的財務報表。逾期提交可面臨港幣 $10,000 罰款及三倍稅款。然而，朗峰會計的實際服務經驗顯示，不少中小企老闆直至收到報稅表才開始張羅帳目，往往令核數及申報工作陷於被動。

朗峰會計負責人 Marx 陳先生表示：「很多老闆對自己公司帳目的實際狀況並不清楚，等到收到報稅表才發現問題，已經十分被動。免費診斷的目的，是讓老闆提早知道自己站在哪個位置，需要做什麼、還有多少時間——掌握清楚，才能從容應對。」

Hashtag: #SetupHK #朗峰會計

The issuer is solely responsible for the content of this announcement.

關於朗峰會計

朗峰會計（SetupHK）自 2014 年起為香港及海外企業提供全方位商業支援，涵蓋成立公司（香港／台灣）、記帳、核數、報稅、公司秘書、申請銀行戶口及公司結業等服務。辦公室設於香港旺角，每年服務數百位客戶，是本地中小企業、初創公司及跨境老闆信賴的一站式商業夥伴。

聯絡朗峰會計

• 官方網站：setuphk.com
• 電話：852-3845-2888
• WhatsApp：852-9248-5734
• 辦公室：旺角彌敦道 707-713 號銀高國際大廈 17 樓 B 室
• Facebook：facebook.com/setuphk

媒體查詢，請聯絡朗峰會計市場推廣部，電話：852-3845-2888。